MEI Pharma To Present at Two Upcoming Investor Conferences
PR Newswire•March 14, 2018
SAN DIEGO, March 14, 2018 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it will webcast a business overview and update by Daniel P. Gold, Ph.D., president and chief executive officer, at each of the following upcoming healthcare conferences:
The Oppenheimer 28th Annual Healthcare Conference at 10:55 a.m. ET on Wednesday, March 21, 2018 in New York, NY.
The 17th Annual Needham Healthcare Conference at 4:30 p.m. ET on Tuesday, March 27, 2018 in New York, NY.
A live audio webcast of each event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma's website at http://www.meipharma.com, or by following the links below in your web browser.
An archived replay of each webcast will be available on MEI Pharma's website for at least 30 days after the live event concludes. About MEI Pharma
MEI Pharma, Inc. (MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine for the treatment of patients with high and very high-risk myelodysplastic syndrome (MDS) (NCT03151304). MEI Pharma's clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase 1b study in patients with relapsed/refractory CLL or follicular lymphoma, and voruciclib, an oral, selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of HER2-negative breast cancer. Pracinostat, ME-401, ME-344 and voruciclib are investigational agents and are not approved for use in the U.S. For more information, please visit www.meipharma.com.
Cane I have put any Cruising on hold if not forever? but at least not until these are at least $25 per share, they have four drugs in the clinic right now!
I reckon if all goes well? that they will be around that figure within the next year, but like I said everything has to go right!
My wife and I have done seven Cruises, I wasn't too impressed with the last two, we had outbreaks of Norovirus on both, and I read that they are a regular occurrence on a lot of cruises now, they can't get rid of it I believe? we were lucky, we didn't get it, but there were plenty aboard who did, but it did rob us of a stopover in Nagasaki Japan and also caused us to arrive in Busan in South Korea a day early, which was a Sunday from memory or a public holiday (memory?) and pretty much everything was closed.
Also we had asked that we didn't want any upgrades whatsoever, we choose the room we want for our cruises, somewhere around the middle of the ship on deck 7 and also an interior room, we find that there is far less ship movement there, but what happened? we were given an upgrade even though we had told them NO UPGRADE in no uncertain terms, we argued for a very long time, my wife even went up to what was our requested room and there was our name on the door, so obviously it had been changed that day? the staff said to us, at least have a look at the upgrade, so we did! where was it? right near the stern of the ship right above the ships engines, yes it did have a porthole view, we were looking at the side of one of the orange ferry/lifeboats, what a load of BS, we ended up with the room we requested in the end after a very long and heated argument, but it left a very sour for us taste let me tell you, that was our last cruise and it may have been our very last trip with them?
KZA Price at posting:
75.0¢ Sentiment: Buy Disclosure: Held
